Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children

NEXT STORY
North America Transient Protein Expression Market Report 2021-2027: Market is Expected Witness High Demand for Systems for Drug Discovery Applications
PREV STORY
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV

author_avatar
NASDAQ Market News

Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301

NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a ...

author_avatar
NASDAQ Market News